Top

Published in:

01-02-2011

Breast Cancer Screening with Mammography

Authors: Bradford R. Hirsch, Gary H. Lyman

Published in: Current Oncology Reports | Issue 1/2011

Abstract

There has been a great deal of controversy regarding the change in breast cancer screening recommendations released by the US Preventive Services Task Force in November 2009. Despite limited new data, the Task Force changed their previous recommendations delaying initial screening of asymptomatic women from age 40 to age 50 and recommending biennial rather than annual breast cancer screening. It is important to fully understand the nuances of the analysis and modeling upon which the revisions were based in order to accurately inform patients of the risks and benefits of breast cancer screening. Several new studies as well as additional guidelines have also been released over the past year which further inform the debate, and a number of commentaries have helped to place the risks and benefit in clinical and societal context.

Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 2009. 151(10): p. 716–26, W-236.

• Park A, P.K., The mammogram melee. Time Magazine, 2009: p. 41-2. This is an excellent discussion of reactions in the medical and lay communities to the change in recommendations.

Berlin, L. and F.M. Hall, More mammography muddle: emotions, politics, science, costs, and polarization. Radiology, 2010. 255(2): p. 311–6.CrossRefPubMed

USPSTF mammography recommendations will result in countless unnecessary breast cancer deaths each year. http://www.acr.org/MainMenuCategories/media_room/FeaturedCategories/PressReleases/USPSTFMammoRecs.aspx.. ACR News Website, 2009: p. Accessed August 3 rd, 2010.

Kerlikowske, K., Evidence-based breast cancer prevention: the importance of individual risk. Ann Intern Med, 2009. 151(10): p. 750–2.PubMed

Jemal, A., et al., Cancer statistics, 2009. CA Cancer J Clin, 2009. 59(4): p. 225–49.CrossRefPubMed

• Nelson, H.D., et al., Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med, 2009. 151(10): p. 727–37, W237-42. This is a discussion of the analysis upon which the changes in recommendations were based.

Humphrey, L.L., et al., Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med, 2002. 137(5 Part 1): p. 347–60.

Autier, P., et al., Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J Clin Oncol, 2009. 27(35): p. 5919–23.CrossRefPubMed

10.

• Gotzsche, P.C. and M. Nielsen, Screening for breast cancer with mammography. Cochrane Database Syst Rev, 2009(4): p. CD001877. This Cochrane review looks at screening with mammography.

11.

Jorgensen, K.J., P.H. Zahl, and P.C. Gotzsche, Overdiagnosis in organised mammography screening in Denmark. A comparative study. BMC Womens Health, 2009. 9: p. 36.CrossRef

12.

Moss, S.M., et al., Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet, 2006. 368(9552): p. 2053–60.CrossRefPubMed

13.

Bjurstam, N., et al., The Gothenburg Breast Screening Trial. Cancer, 2003. 97(10): p. 2387–96.

14.

• Petitti, D.B., et al., Breast cancer screening: from science to recommendation. Radiology, 2010. 256(1): p. 8–14. USPSTF members provide further explanations of the change in recommendations.

15.

Bevers, T.B., et al., NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw, 2009. 7(10): p. 1060–96.PubMed

16.

• Mandelblatt, J.S., et al., Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med, 2009. 151(10): p. 738–47. This article presents the models used by the USPSTF to compare different age cutoffs and screening frequencies.

17.

Nystrom, L., et al., Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet, 2002. 359(9310): p. 909–19.CrossRefPubMed

18.

Brewer, N.T., T. Salz, and S.E. Lillie, Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med, 2007. 146(7): p. 502–10.PubMed

19.

Elmore, J.G., et al., Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med, 1998. 338(16): p. 1089–96.CrossRefPubMed

20.

Hofvind, S., S. Thoresen, and S. Tretli, The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program. Cancer, 2004. 101(7): p. 1501–7.CrossRefPubMed

21.

Olivotto, I.A., L. Kan, and A.J. Coldman, False positive rate of screening mammography. N Engl J Med, 1998. 339(8): p. 560; author reply 563.

22.

Duffy, S.W., et al., Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res, 2005. 7(6): p. 258–65.CrossRefPubMed

23.

Moss, S., Overdiagnosis and overtreatment of breast cancer: overdiagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res, 2005. 7(5): p. 230–4.CrossRefPubMed

24.

Olsen, A.H., et al., Overdiagnosis, sojourn time, and sensitivity in the Copenhagen mammography screening program. Breast J, 2006. 12(4): p. 338–42.CrossRefPubMed

25.

Paci, E., et al., Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy. Breast Cancer Res, 2006. 8(6): p. R68.

26.

Murphy, A.M., Mammography screening for breast cancer: a view from 2 worlds. JAMA, 2010. 303(2): p. 166-7.CrossRefPubMed

27.

Woloshin, S. and L.M. Schwartz, The benefits and harms of mammography screening: understanding the trade-offs. JAMA, 2010. 303(2): p. 164-5.CrossRefPubMed

28.

Berg, W.A., Benefits of screening mammography. JAMA, 2010. 303(2): p. 168-9.

29.

Dickersin, K., et al., The background review for the USPSTF recommendation on screening for breast cancer. Ann Intern Med, 2010. 152(8): p. 537; author reply 538-9.

30.

Lyman, G.H., Breast cancer screening: science, society and common sense. Cancer Invest, 2010. 28(1): p. 1–6.CrossRefPubMed

31.

Elmore, J.G., et al., Does litigation influence medical practice? The influence of community radiologists' medical malpractice perceptions and experience on screening mammography. Radiology, 2005. 236(1): p. 37–46.

32.

DeAngelis, C.D. and P.B. Fontanarosa, US Preventive Services Task Force and breast cancer screening. JAMA, 2010. 303(2): p. 172-3.CrossRefPubMed

33.

Wever, C., Federal Task Force on Preventive Care Faces New Challenge Under Health Law. Kaiser Health News, 2010.

Title: Breast Cancer Screening with Mammography
Authors: Bradford R. Hirsch
Gary H. Lyman
Publication date: 01-02-2011
Publisher: Current Science Inc.
Published in: Current Oncology Reports / Issue 1/2011
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-010-0142-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

The Need for Axillary Dissection in Patients with Positive Axillary Sentinel Lymph Nodes

Obesity and Cancer Risk: Recent Review and Evidence

Denosumab in Breast Cancer

The Need to Examine Metastatic Tissue at the Time of Progression of Breast Cancer: Is Re-biopsy a Necessity or a Luxury?

The Place for Eribulin in the Treatment of Metastatic Breast Cancer

Prostate Cancer Screening

Keynote webinar | Spotlight on antibody–drug conjugates in cancer